Prabhudas Lilladher analysis of Q2FY23 result
HCG’s consolidated post IND AS EBITDA grew healthy 21% YoY (4% QoQ) to Rs 747mn, in line with our estimates (Rs754mn). Adjusted for one time consulting (Rs50mn) and ESOP related charges (Rs12.9mn); was up by 28% YoY. Existing centers reported strong profitability with EBITDA growth of 30% YoY (4% QoQ) to Rs777mn, while new centers reported EBITDA at Rs 95mn (Rs 195mn in H1FY23). Margins improved by 10bps QoQ (25bps YoY) to 17.8% on cost rationalization initiatives. Margins adjusted for one off were at 19.3%.
.
HCG’s asset light approach with focus on partnering has made its business model – capital efficient and scalable. The company operates most of its Comprehensive Cancer Centre (CCC) on lease/rental basis with HCG investing only in equipment’s. Out of 25 HCG’s CCC, only four are on owned land. HCG is in a consolidation mode and given reducing capex intensity, we expect profitability to improve further.
| Subscribe To Our Free Newsletter |
